CV Sciences (CVSI) Total Debt Growth (1y) (2016 - 2026)
CV Sciences (CVSI) Total Debt Growth (1y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.42 Bn | 87.55 Bn | - | -11.90% |
| 2 | Teva Pharmaceutical Industries | 35.86 Bn | 32.12 Bn | 1.97 Bn | -0.14% |
| 3 | Zoetis | 32.46 Bn | 30.52 Bn | 1.62 Bn | 37.52% |
| 4 | Takeda Pharmaceutical | 27.52 Bn | 23.46 Bn | 4.39 Bn | -2.81% |
| 5 | United Therapeutics | 23.15 Bn | 20.99 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.17 Bn | 21.17 Bn | - | - |
| 7 | Viatris | 20.32 Bn | 18.51 Bn | 1.16 Bn | -9.53% |
| 8 | Neurocrine Biosciences | 17.74 Bn | 16.42 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.63 Bn | 12.20 Bn | 785.00 Mn | -13.33% |
| 10 | CV Sciences | 4.11 Mn | 3.80 Mn | 1.56 Mn | -94.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -94.32% |
| Dec 31, 2025 | 143.57% |
| Dec 31, 2022 | 123.74% |
| Mar 31, 2022 | 375.21% |
| Mar 31, 2018 | 63.25% |
| Dec 31, 2017 | 171.50% |
| Sep 30, 2017 | -56.33% |
| Jun 30, 2017 | -41.59% |
| Mar 31, 2017 | -11.38% |
| Dec 31, 2016 | 222.06% |